MX388409B - Composiciones y metodos para tratar canceres. - Google Patents
Composiciones y metodos para tratar canceres.Info
- Publication number
- MX388409B MX388409B MX2016016507A MX2016016507A MX388409B MX 388409 B MX388409 B MX 388409B MX 2016016507 A MX2016016507 A MX 2016016507A MX 2016016507 A MX2016016507 A MX 2016016507A MX 388409 B MX388409 B MX 388409B
- Authority
- MX
- Mexico
- Prior art keywords
- gsk3î2
- hdac
- methods
- medical conditions
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 4
- 108090000353 Histone deacetylase Proteins 0.000 abstract 4
- 230000009977 dual effect Effects 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011413P | 2014-06-12 | 2014-06-12 | |
| PCT/US2015/035659 WO2015192078A1 (en) | 2014-06-12 | 2015-06-12 | Compositions and methods for treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016507A MX2016016507A (es) | 2017-04-27 |
| MX388409B true MX388409B (es) | 2025-03-19 |
Family
ID=54834452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016507A MX388409B (es) | 2014-06-12 | 2015-06-12 | Composiciones y metodos para tratar canceres. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10029997B2 (enExample) |
| EP (2) | EP4306173A3 (enExample) |
| JP (2) | JP6663863B2 (enExample) |
| KR (1) | KR102567244B1 (enExample) |
| CN (1) | CN106794175B (enExample) |
| AU (3) | AU2015274334B2 (enExample) |
| CA (1) | CA2950774C (enExample) |
| ES (1) | ES2960601T3 (enExample) |
| MX (1) | MX388409B (enExample) |
| WO (1) | WO2015192078A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015192078A1 (en) | 2014-06-12 | 2015-12-17 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| CN115778943B (zh) * | 2020-02-26 | 2023-11-10 | 上海科技大学 | 秦皮素在抗冠状病毒中的应用 |
| CN111658766A (zh) * | 2020-07-06 | 2020-09-15 | 陈长宏 | GSK3β及其激动剂在上皮源性恶性肿瘤治疗与康复中的应用 |
| WO2024019667A1 (en) * | 2022-07-21 | 2024-01-25 | Agency For Science, Technology And Research | Method of inhibiting epithelial-mesenchymal transition and cancer metastasis |
| CN115197167B (zh) * | 2022-07-22 | 2023-07-28 | 中国药科大学 | 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711492A (en) * | 1970-12-08 | 1973-01-16 | Basf Ag | Thiadiazolidinediones |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| EP0948489A1 (en) * | 1996-12-17 | 1999-10-13 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
| US6045925A (en) | 1997-08-05 | 2000-04-04 | Kansas State University Research Foundation | Encapsulated nanometer magnetic particles |
| CA2366264A1 (en) * | 1999-04-02 | 2000-10-12 | Bristol-Myers Squibb Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase |
| AP2003002908A0 (en) * | 2001-05-11 | 2003-12-31 | Pharmacia Corp | Aromatic sulfone hydroxamates and their use as protease inhibitors |
| EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US6676729B2 (en) | 2002-01-02 | 2004-01-13 | International Business Machines Corporation | Metal salt reduction to form alloy nanoparticles |
| EP1339075A1 (en) | 2002-02-25 | 2003-08-27 | Motorola, Inc. | Magnetic nanomaterials and synthesis method |
| US6878445B2 (en) | 2002-03-08 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Nanoparticle coated material and production method of same |
| JP2006504755A (ja) | 2002-10-15 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | Ｇｓｋ−３阻害薬としてのピリダジン化合物 |
| DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
| WO2004101512A2 (en) * | 2003-05-13 | 2004-11-25 | Smithkline Beecham Corporation | Naphthyridine integrase inhibitors |
| GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| US7396589B2 (en) | 2003-07-31 | 2008-07-08 | Industrial Technology Research Institute | Core-shell magnetic nanoparticles comprising an inner-transition element |
| TW593158B (en) | 2003-07-31 | 2004-06-21 | Ind Tech Res Inst | Magnetic nanoparticle |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| GB0402496D0 (en) * | 2004-02-04 | 2004-03-10 | Argenta Discovery Ltd | Novel compounds |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| GB0418328D0 (en) | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US7700193B2 (en) | 2005-04-08 | 2010-04-20 | Industrial Technology Research Institute | Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof |
| US20070264199A1 (en) | 2005-09-26 | 2007-11-15 | Labhasetwar Vinod D | Magnetic nanoparticle composition and methods for using the same |
| EP1976976A4 (en) * | 2005-12-23 | 2010-12-15 | Univ Rochester | TREATMENT OF NEURO-AIDS USING INHIBITORS OF GLYCODY SYNTHASE KINASE (GSK) -3 |
| US20090142337A1 (en) | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| AU2007275686B2 (en) * | 2006-07-18 | 2013-10-31 | University Of Rochester | Thiadiazolidinone derivatives |
| WO2008016123A1 (en) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| EP2170814B1 (en) * | 2007-06-12 | 2016-08-17 | Achaogen, Inc. | Antibacterial agents |
| CN101896177A (zh) * | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| US20120015942A1 (en) * | 2010-07-19 | 2012-01-19 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| BR112014000371A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| US9371299B2 (en) * | 2012-02-24 | 2016-06-21 | Asd Therapeutics Partners, Llc | Thiadiazolidinediones as GSK-3 inhibitors |
| JP5722264B2 (ja) | 2012-03-23 | 2015-05-20 | 株式会社日立ハイテクノロジーズ | データ処理装置、データ容量増加抑制方法 |
| EP2917202B1 (en) | 2012-11-07 | 2018-05-02 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors and their use in therapy |
| CN103848795B (zh) | 2014-03-07 | 2016-08-17 | 山东大学 | 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
| WO2015192078A1 (en) | 2014-06-12 | 2015-12-17 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
-
2015
- 2015-06-12 WO PCT/US2015/035659 patent/WO2015192078A1/en not_active Ceased
- 2015-06-12 KR KR1020177000702A patent/KR102567244B1/ko active Active
- 2015-06-12 EP EP23188783.7A patent/EP4306173A3/en active Pending
- 2015-06-12 MX MX2016016507A patent/MX388409B/es unknown
- 2015-06-12 ES ES15806839T patent/ES2960601T3/es active Active
- 2015-06-12 CN CN201580042796.XA patent/CN106794175B/zh active Active
- 2015-06-12 JP JP2016572482A patent/JP6663863B2/ja active Active
- 2015-06-12 EP EP15806839.5A patent/EP3154544B1/en active Active
- 2015-06-12 US US15/317,559 patent/US10029997B2/en active Active
- 2015-06-12 CA CA2950774A patent/CA2950774C/en active Active
- 2015-06-12 AU AU2015274334A patent/AU2015274334B2/en active Active
-
2018
- 2018-06-19 US US16/012,536 patent/US10266505B2/en active Active
-
2019
- 2019-03-04 US US16/292,011 patent/US10836735B2/en active Active
-
2020
- 2020-02-17 JP JP2020023904A patent/JP7015856B2/ja active Active
- 2020-10-08 US US17/066,397 patent/US20210276964A1/en not_active Abandoned
-
2021
- 2021-03-17 AU AU2021201667A patent/AU2021201667B2/en active Active
-
2023
- 2023-02-16 AU AU2023200895A patent/AU2023200895A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6663863B2 (ja) | 2020-03-13 |
| EP4306173A3 (en) | 2024-04-10 |
| US20210276964A1 (en) | 2021-09-09 |
| EP3154544A1 (en) | 2017-04-19 |
| US10029997B2 (en) | 2018-07-24 |
| AU2021201667A1 (en) | 2021-04-08 |
| CN106794175A (zh) | 2017-05-31 |
| US20170121297A1 (en) | 2017-05-04 |
| US10836735B2 (en) | 2020-11-17 |
| US20190194152A1 (en) | 2019-06-27 |
| MX2016016507A (es) | 2017-04-27 |
| JP7015856B2 (ja) | 2022-02-03 |
| CN106794175B (zh) | 2020-06-09 |
| AU2021201667B2 (en) | 2022-11-17 |
| AU2015274334B2 (en) | 2020-12-17 |
| JP2020090537A (ja) | 2020-06-11 |
| AU2015274334A1 (en) | 2016-12-15 |
| ES2960601T3 (es) | 2024-03-05 |
| WO2015192078A1 (en) | 2015-12-17 |
| CA2950774A1 (en) | 2015-12-17 |
| US20180297965A1 (en) | 2018-10-18 |
| EP4306173A2 (en) | 2024-01-17 |
| KR20170015507A (ko) | 2017-02-08 |
| KR102567244B1 (ko) | 2023-08-16 |
| EP3154544B1 (en) | 2023-08-02 |
| EP3154544A4 (en) | 2017-12-20 |
| CA2950774C (en) | 2023-03-21 |
| JP2017523141A (ja) | 2017-08-17 |
| US10266505B2 (en) | 2019-04-23 |
| AU2023200895A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| MX2018011792A (es) | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). | |
| PH12015502028A1 (en) | Ido inhibitors | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| EA201690306A1 (ru) | Ингибиторы ido | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| CR20200362A (es) | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
| MX381092B (es) | Inhibidores de fucosidasa. | |
| EA201792288A1 (ru) | Способы лечения рака |